Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7523952 | 0.80 | HIF1A (0.39) | HIF1ATSHRMAOAMAOBMAPT | |
| SCHEMBL436282 | 0.78 | ALOX15 (0.47) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL1774553 | 0.77 | MEN1 (0.50) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL7283602 | 0.77 | MEN1 (0.50) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL5497459 | 0.77 | MEN1 (0.50) | HIF1ATSHRMAOAMAOBFAAH | |
| Hydrochloric Acid SCHEMBL30374046 | 0.77 | ALOX15 (0.46) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL7435959 | 0.77 | MEN1 (0.50) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL24709159 | 0.74 | TSHR (0.40) | HIF1ATSHRMAOAMAOBFAAH | |
| SCHEMBL7523949 | 0.73 | — | — | |
| SCHEMBL16468734 | 0.73 | HIF1A (0.41) | HIF1ATSHRMAPTKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015110935-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20140271468-A1 | ASTHMA IMAGING | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2008101231-A2 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING KIDNEY DISEASE | ENDOCYTE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271468-A1 | ASTHMA IMAGING | CYSLTR1, FCER2, MRGPRX2 | HIF1A 761/4885TSHR 1895/4885DDAH1 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.